Physician profile
Constantine C Boiangiu
NPI 1265645436
$4,138.45
in general payments reported to CMS, 2019-2025
26 companies · $534 in 2025
The $534 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,446 · 2020: $381 · 2021: $516 · 2022: $411 · 2023: $667 · 2024: $184 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,384.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $789.53 | 2019 | |
| Novartis Pharmaceuticals Corporation | $641.94 | 2019-2025 | |
| Abbott Laboratories | $326.84 | 2019-2024 | Gallant, Assurity, Cardiomems |
| Abiomed | $289.00 | 2019-2023 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $270.76 | 2019-2025 | Lifevest |
| Kestra Medical Technology Services, INC. | $256.05 | 2022-2025 | Assure Wcd |
| Astrazeneca Pharmaceuticals Lp | $202.81 | 2020-2024 | Andexxa, Wainua |
| Kowa Pharmaceuticals America, INC. | $202.54 | 2023 | Livalo, Seglentis |
| Amgen INC. | $170.49 | 2019-2024 | Repatha |
| Boston Scientific Corporation | $166.38 | 2019 | |
| Cvrx, INC. | $139.57 | 2024-2025 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.27 | 2019-2022 | |
| Pfizer INC. | $95.05 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $81.37 | 2021-2023 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $64.99 | 2024-2025 | Eliquis, Camzyos |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $49.94 | 2020-2021 | |
| Kiniksa Pharmaceuticals, Ltd. | $43.85 | 2021-2023 | Arcalyst |
| Esperion Therapeutics, INC. | $38.77 | 2020-2025 | Nexletol |
| Biotronik INC. | $36.28 | 2021 | |
| Edwards Lifesciences Corporation | $36.27 | 2025 | Pascal |
| Abbvie INC. | $27.83 | 2022 | |
| Bardy Diagnostics, INC. | $25.00 | 2019 | |
| Impulse Dynamics (USA) INC. | $23.29 | 2022 | |
| Sanofi-Aventis U.S. LLC | $20.17 | 2023 | |
| Bridgebio Pharma, INC. | $19.63 | 2025 | Attruby |
| Janssen Pharmaceuticals, INC | $15.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Constantine Boiangiu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.